Featured Research

from universities, journals, and other organizations

Sloppy shipping of human retina leads researchers to discover new treatment path for eye disease

Date:
May 4, 2012
Source:
Indiana University
Summary:
Sloppy shipping of a donated human retina to a researcher studying a leading cause of vision loss has inadvertently helped uncover a previously undetected mechanism causing the disease. The discovery has led researchers to urge review of how millions of dollars are spent investigating the cause of a type of age-related macular degeneration called choroidal neovascularization.

Sloppy shipping of a donated human retina to an Indiana University researcher studying a leading cause of vision loss has inadvertently helped uncover a previously undetected mechanism causing the disease. The discovery has led researchers to urge review of how millions of dollars are spent investigating the cause of a type of age-related macular degeneration called choroidal neovascularization.

Working at IU's Biocomplexity Institute, postdoctoral researcher Abbas Shirinifard had hit a brick wall trying to develop detailed computer simulations of the behaviors and interactions of the cells and membranes composing the rear of the retina and its supporting vasculature. In choroidal neovascularization (CNV), blood vessels that supply the eye with oxygen and nutrients and originate in the choroid just behind the eye abruptly break into the retina and disrupt it. Blindness can follow in a matter of months.

Two current treatments for CNV either kill the invading blood vessels with drugs injected into the eye (also damaging the retina and killing needed blood vessels as well) or laser-heat the blood vessels, which can cause damaging retinal scars. Yet with 9,000 research papers published on CNV over the past 10 years, neither treatment still addresses the underlying problems that cause the blood vessels to invade, so relapses are common and many patients still lose vision within a year or two.

A serendipitous accident in which a donated human retina from an eye bank was severely shaken during shipping inspired Shirinifard to try again with a series of new simulations. Upon examination of the eye, Shirinifard and Biocomplexity Institute senior microscopist Sherry Clendenon found that regions of the retina with invading blood vessels had separated from their underlying membrane, while regions that had stayed attached showed much less invasion, suggesting that adhesion might be an essential but overlooked mechanism in maintaining the retina's structure.

Using an open-source modeling software program called CompuCell3D developed by the Biocomplexity Institute in collaboration with the University of Washington and the University of Wisconsin under National Institutes of Health funding, the team quickly began extending existing simulations to study the effects of adhesion defects.

"The simulations showed that reduced adhesion in the retina could indeed lead to its invasion by blood vessels," Shirinifard said. "But the complex structure of the retina meant that many types of adhesion could be important -- the three most prominent being between the pigmented retinal cells (the black lining of the eye) and Bruch's membrane (the substrate that supports the retina), between adjacent pigmented retinal cells, and between pigmented retinal cells and the overlying photoreceptors."

Those variables, the team realized, could be independent of one another or interact in complex ways, and knowing that the rate and type of progression of the disease varies greatly from patient to patient, they needed to examine many examples of each adhesion combination.

That's when Quarry, the IU computer cluster operated by the Office of the Vice President for Information Technology, was called in to push out 32,000 hours of calculations. "We were able to model the interactions of different degrees of impairment of each type of adhesion and the variation from case to case," Shirinifard said. "Amazingly, these simulations were able to replicate the complex spectrum of CNV seen in the clinic."

Simulations of adhesion defects caused by reduced adhesion between pigmented retinal cells and Bruch's membrane -- the type of CNV typical of aging -- produced a pattern and frequency of invasion agreeing with that in the clinic. Similarly, reduced adhesion between neighboring pigmented retinal cells, typical of inflammation due to severe infection, produced a pattern of invasion agreeing with that seen in young adults.

By combining thousands of simulations, Shirinifard was able to produce maps that related defects in each type of adhesion to the risk of each type of invasion. In turn, he could show that cell adhesion is key to keeping blood vessels out of the retina and that combination defects in the different types of adhesion are sufficient to determine the probability, pattern and rate of progression of CNV.

The full results of one of the most complex tissue evolution models ever deployed were just published in PLoS Computational Biology, and while the team has yet to move toward developing new CNV therapies, the work should have great significance in the search for better therapies, according to Biocomplexity Institute Director James Alexander Glazier, a co-author on the paper and professor in the IU Bloomington College of Arts and Sciences' Department of Physics.

"Hundreds of millions of dollars are spent annually to develop drugs and treatment approaches based on the two commonly hypothesized CNV initiation and progression mechanisms," he said. "Because the current work shows that neither hypothesized mechanism is an important cause of CNV, that money and effort are extremely unlikely to improve outcomes for patients. Scientists have been barking up the wrong tree. Instead, a search for therapies which restore normal adhesion in the eye is much more likely to produce effective treatments. In addition, the detailed agreement between simulation and clinical observations suggests that new approaches to measuring adhesion in patients would allow much more accurate predictions of the prognosis for individual patients."

The researchers believe these results will also have a much broader impact, as they apply to any tissue -- like the gut and the lung -- in which a basement membrane separates a capillary network from a nearby epithelium.

"The relationships between specific classes of adhesion failures and the types and dynamics of CNV in the eye simulations should carry over to the neovascularization-dependent pathologies of those tissues and to invasion of those tissues in cancer progression," Shirinifard said.


Story Source:

The above story is based on materials provided by Indiana University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Abbas Shirinifard, James Alexander Glazier, Maciej Swat, J. Scott Gens, Fereydoon Family, Yi Jiang, Hans E. Grossniklaus. Adhesion Failures Determine the Pattern of Choroidal Neovascularization in the Eye: A Computer Simulation Study. PLoS Computational Biology, 2012; 8 (5): e1002440 DOI: 10.1371/journal.pcbi.1002440

Cite This Page:

Indiana University. "Sloppy shipping of human retina leads researchers to discover new treatment path for eye disease." ScienceDaily. ScienceDaily, 4 May 2012. <www.sciencedaily.com/releases/2012/05/120504105857.htm>.
Indiana University. (2012, May 4). Sloppy shipping of human retina leads researchers to discover new treatment path for eye disease. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2012/05/120504105857.htm
Indiana University. "Sloppy shipping of human retina leads researchers to discover new treatment path for eye disease." ScienceDaily. www.sciencedaily.com/releases/2012/05/120504105857.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins